Arber lab

Our overall goal is to develop novel targeted immunotherapies for patients with hematologic malignancies. The group develops adoptive T cell therapies with native or engineered receptors and evaluates combinatorial strategies. The objective is to efficiently target tumor cells, mitigate immunosuppressive tumor microenvironment factors, favor tumor-targeted migration and longevity of transferred T cells, control potential toxicities, identify novel personalized targets, and move developments to the clinic. ...

Team

Caroline Arber Barth

Associate Professor, Department of Oncology UNIL & CHUV, Ludwig adjunct scientist, Ludwig Institute for Cancer Research Lausanne

caroline.arber@unil.ch

Other members

Danisha (Yashashvi) Bhugowon

Laboratory Technician, UNIL & CHUV

Damla Inel

PhD Student, UNIL & CHUV

Jan Rath

PhD Student, UNIL & CHUV

Maude Varrin

Laboratory Technician, UNIL & CHUV

Benita Wolf

Research Associate, UNIL & CHUV

Selected Publications

Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring

Perez C, Gruber I, Arber C

Frontiers in immunology – 2020 Nov 11

Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells.

Bajwa G, Lanz I, Cardenas M, Brenner MK, Arber C

Journal for immunotherapy of cancer – 2020 Nov

Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4+ T cells.

Rath JA, Bajwa G, Carreres B, (...), Brenner MK, Gfeller D, Arber C

Science advances – 2020 Jul 3

Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.

Rath JA, Arber C

Cells – 2020 Jun 18

c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals.

Nishimura CD, Brenner DA, Mukherjee M, (...), Brenner MK, Lin CY, Arber C

Blood – 2017 Oct 27

Reprogramming cellular functions with engineered membrane proteins.

Arber C, Young M, Barth P

Current opinion in biotechnology – 2017 Jul 11

CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.

Bonifant CL, Szoor A, Torres D, (...), Song XT, Redell M, Gottschalk S

Molecular therapy : the journal of the American Society of Gene Therapy – 2016 Jun 6

Survivin-specific T cell receptor targets tumor but not T cells.

Arber C, Feng X, Abhyankar H, (...), Barth P, Dotti G, Savoldo B

The Journal of clinical investigation – 2014 Nov 21

Mouse models in bone marrow transplantation and adoptive cellular therapy.

Arber C, Brenner MK, Reddy P

Seminars in hematology – 2013 Jun 11

The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.

Arber C, Abhyankar H, Heslop HE, (...), Liu H, Dotti G, Savoldo B

Gene therapy – 2013 May 23

Graft source determines human hematopoietic progenitor distribution pattern within the CD34(+) compartment.

Arber C, Halter J, Stern M, (...), Rovó A, Gratwohl A, Tichelli A

Bone marrow transplantation – 2010 Aug 16

Black hole in the lung.

Cantoni N, Weisser M, Frei R, Lardinois D, Arber C

Bone marrow transplantation – 2010 Mar 29

Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay.

Arber C, Bertrand G, Halter J, (...), Boehlen F, Kaplan C, Gratwohl A

British journal of haematology – 2007 Oct

Septic polyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment.

Arber C, Buser A, Heim D, (...), Tichelli A, Passweg J, Gratwohl A

Bone marrow transplantation – 2007 Jul 9

Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome.

Arber C, Buser A, Heim D, (...), Gratwohl A, Tichelli A, Passweg JR

European journal of haematology – 2006 Mar

Related news

Events

AGORA Progress Report Series, June 14th

Events

AGORA Progress Report Series, June 7th